PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Clonazepam - Parkinson's disease
PAD Profile : Clonazepam - Parkinson's disease
Keywords :
RBD, rapid eye movement disorder, PD, REM
Brand Names Include :
Rivotril
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Tolcapone
- Apomorphine hydrochloride
- Safinamide
- Opicapone
- Co-beneldopa (Benserazide/levodopa)
- Co-careldopa (Carbidopa/levodopa)
- Pramipexole
- Ropinirole hydrochloride
- Bromocriptine
- Pergolide mesilate
- Cabergoline
- Rasagiline mesilate
- Selegiline hydrochloride
- Entacapone
- Amantadine hydrochloride
- Orphenadrine hydrochloride
- Procyclidine hydrochloride
- Trihexyphenidyl hydrochloride
- Melatonin
- Rotigotine
- Levodopa/carbidopa/entacapone
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Clonazepam or melatonin (generic 2mg MR tablets) may be considered to treat rapid eye movement sleep behaviour disorder (RBD) in people with Parkinson's Disease and sleep disturbance (unlicensed use).
A medicines review should first be undertaken to address any possible pharmacological causes.
Clonazepam or melatonin for this condition should only be initiated on request from a Parkinson's specialist
Associated BNF Codes
04. Central Nervous System
04.08.02. Drugs used in status epilepticus